Please ensure Javascript is enabled for purposes of website accessibility

Why Johnson & Johnson Is a Retiree's Dream Stock

By Justin Pope – Sep 10, 2021 at 6:19AM

Key Points

  • Savers won't earn much interest from banks accounts or CDs, making relatively safe blue-chip stocks an attractive alternative.
  • Johnson & Johnson offers top-notch financials, steady growth, a reliable business, and an increasing dividend.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If you're looking for a quality stock that will let you sleep well at night, this health industry giant might fit the bill.

Stocks as a rule are riskier than bonds or other fixed-income assets, but the downside to those right now is that Treasury bonds, bank accounts, and CDs are paying very low interest. As such, many retirees may be looking for safe-haven investments in stocks -- quality businesses that can be expected to grow steadily while delivering some dividend income in the process.

Johnson & Johnson (JNJ 0.13%) is a diversified titan in arguably the most critical industry in the world: healthcare. Its long track record of success and dividend payouts could make it "the" stock for retirees.

A dominant business in healthcare

Johnson & Johnson is behind some of the most well-known health and personal care brands in the world, including:

  • Band-Aid
  • Tylenol
  • Johnson's baby products
  • Benadryl
  • Motrin
  • Listerine
Retiree sitting on a couch and smiling.

Image Source: Getty Images

And these products came from its consumer health segment, which is actually the smallest part of the company. Johnson & Johnson is an enormous operation with three primary divisions -- consumer health, pharmaceutical drugs, and medical devices. It did more than $82 billion in revenue in 2020.

The global healthcare industry's revenues are forecast to top $10 trillion annually in 2022. As medical care advances in developed countries and the quality of care continues to improve in emerging economies, Johnson & Johnson will have a large sandbox to grow in.

Top-notch financials

There are many healthcare businesses to invest in, but Johnson & Johnson's financials set it apart from most. Its pharmaceutical business leads the way, contributing 55% of total revenue, followed by medical devices at 28%, and consumer health providing the balance.

Johnson & Johnson is extremely profitable, turning $20.2 billion of its 2020 revenue into free cash flow, a conversion rate of 24%. Its balance sheet currently holds $25.2 billion in cash, equivalents, and marketable securities. And the company's AAA credit rating from Standard & Poor's is the highest the agency bestows -- and is better than the current rating of the U.S. government. In other words, Johnson & Johnson is considered less likely to default on its debt than Washington, which is almost mind-bending to think about. That's some serious financial security.

It literally pays to hold the stock

Thanks to all the cash Johnson & Johnson generates, shareholders have enjoyed many years of rising dividend payments. Its current annual payout is $4.24 per share, which at recent share prices amounts to a yield of 2.46%. That's not too shabby, considering that banks now pay interest of just 0.06% on average.

The company has also increased its payout annually for the past 59 years -- making it a Dividend King -- and has boosted it at an average rate of 6.45% over the past decade. In addition, its dividend payout ratio remains affordable at 62%, so Johnson & Johnson has plenty of room to continue steadily increasing its dividend from here.

It's not all perfect

There is a lot to like in Johnson & Johnson, but no company is perfect.  There are more than 34,000 open lawsuits against Johnson & Johnson over its talcum baby powder, which was alleged to contain cancer-causing asbestos; the legal costs are estimated to be approaching $4 billion.

The company has been setting aside a fund to help cover these legal costs and is allegedly attempting to spin off its talcum powder business as a separate company to separate its liability from the rest of Johnson & Johnson's assets.

Johnson & Johnson's enormous size and balance sheet are likely to make the talcum lawsuits a short-term hiccup. Still, it's worth recognizing that healthcare companies are not immune from trouble.

Putting it all together

Johnson & Johnson is expected to bring in earnings per share of $9.67 for 2021, giving the stock a forward price-to-earnings ratio of 17.8. The S&P 500 trades at a forward P/E ratio of 22, so Johnson & Johnson's valuation is discounted despite its stellar fundamentals.

Analysts expect the company's profits to grow by 7% to 8% annually, which will allow it to continue doling out dividend increases and maintain its great financials, so retirees can probably expect more of the same from Johnson & Johnson.

Justin Pope has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$177.24 (0.13%) $0.23

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.